FDA’s Scandal In Waiting?
Executive Summary
Headlines about potential carcinogens in the drug supply have been a chronic, low-level challenge for the US FDA’s reputation in recent years. A recent Congressional hearing shows how much tinder is now laid for a potential flare up into a full-on crisis in confidence in the agency.
You may also be interested in...
Quality Lowdown: FDA Defends Nitrosamine Testing Methods While US, EU Enforcement Continues
The crisis of nitrosamine contamination in prescription drug products continues to roil the world’s health authorities and prompts debate on the different approaches used to measure these impurities. Meanwhile, an Austrian firm gets inspected despite the pandemic and yet another homeopathic firm gets an FDA warning letter.
US FDA And Congress: Criticism Of Leadership Ramping Up, But Bipartisan Truce Holds For Now
Senate Finance Committee’s hearing on FDA’s overseas inspection program suggests that agency’s status as a rare focus for bipartisan support amid the Trump Presidency is getting more tenuous – but still holding for the time being.
US FDA And Congress: Criticism Of Leadership Ramping Up, But Bipartisan Truce Holds For Now
Senate Finance Committee’s hearing on FDA’s overseas inspection program suggests that agency’s status as a rare focus for bipartisan support amid the Trump Presidency is getting more tenuous – but still holding for the time being.